# Artbio Raises $132M Series B to Advance Radiopharmaceutical Pipeline in Prostate Cancer

> financing · REPORTED · 2025-07-29

Radiopharmaceuticals-focused Artbio secured a $132 million Series B round led by Sofinnova Investments and B Capital, with participation from Qatar Investment Authority and Alexandria Venture Investments among others. Funds will support Phase 2 development of lead asset AB001 for metastatic castration-resistant prostate cancer and bolster manufacturing supply chain.

About Artbio: Artbio is a clinical-stage biotechnology company developing targeted alpha-particle radiopharmaceuticals, with its lead candidate AB001 designed to treat metastatic castration-resistant prostate cancer by delivering localized radiation to tumor cells.

- Company: Artbio
- Sector: biotech
- Primary source: https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.